Q-omics provides the consensus-scored NCR3LG1 profile across patient tissues and cancer cell-line models. NCR3LG1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCR3LG1 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, NCR3LG1 RNA expression shows 19,662 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where NCR3LG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCR3LG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCR3LG1 survival associations across molecular data types. NCR3LG1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCR3LG1 RNA expression–survival associations across cancer types. High NCR3LG1 expression shows unfavorable associations in UVM, ACC and BLCA, but favorable associations in KIRC, READ and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCR3LG1 RNA expression.
This table summarizes NCR3LG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NCR3LG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCR3LG1 shows lower tumor expression in THCA and higher tumor expression in COAD, KICH, KIRC, HNSC and STAD. The COAD box plot shows higher NCR3LG1 RNA expression in tumor versus normal tissue (log2 FC = +1.290, t-test p < 0.001).
This table shows molecular features associated with NCR3LG1 in patient tissues and cancer cell lines. In patient samples, NCR3LG1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCR3LG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
